ProSomnus Sleep Technologies announced the formation of its inaugural Medical Advisory Board, significant enhancements to its RPMO₂ platform, and growing clinical evidence supporting precision oral appliance therapy (OAT), including results from the FLOSAT study. These advancements will be highlighted during the company’s participation at CHEST 2026, October 19-21, 2026, in […]
Tag: RPMO2
ProSomnus and MonitAir Collaborate to Enhance Connected Care for OSA
ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“MonitAir”), the premier digital health and tele-monitoring platform for sleep medicine announced a collaboration to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ […]
ProSomnus Receives FDA Class II Clearance for RPMO₂ OSA Device
ProSomnus Sleep Technologies announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂ OSA Device under the product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765). The RPMO2 OSA Device is the first theragnostic device for sleep medicine, incorporating both precision […]
ProSomnus Announces Record Revenues as it Emerges from Reorganization
ProSomnus Sleep Technologies announced record revenues for the quarter that ended June 30, 2024, as it formally emerged from reorganization on August 5, 2024. Revenues for the second quarter totaled a record $9.1 million reflecting increasing orders for the Company’s precision intraoral medical devices. These quarterly results reflect a 22% […]












